Document is current
Any future updates will be listed below
-
Authors
Lavoro, Alessandro
Falzone, Luca
Gattuso, Giuseppe
Conti, Giuseppe N.
Caltabiano, Rosario
Madonna, Gabriele
Capone, Mariaelena
McCubrey, James A.
Ascierto, Paolo A.
Libra, Massimo
Candido, Saverio http://orcid.org/0000-0003-1255-6666
- License Information
-
More Information
Article History
Received: 5 June 2024
Accepted: 18 August 2024
First Online: 2 October 2024
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Boards at the contributing institutions. The Ethics Committee of Fondazione “G. Pascale” of Naples approved the study with protocol n. 33/17 and 37/22 oss. The patients/participants provided their written informed consent to participate in this study.
: Not applicable.
: Dr. Paolo A. Ascierto has/had a consultant/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Sandoz, Immunocore, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX, Replimmune, Bayer, Erasca. He also received research funding from Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi. Travel support by Pfizer, Bio-Al Health, Replimmune. The other authors declare no competing interest.
